Sullivan

Sullivan Biotech appears to be an early-stage oncology-focused biotechnology venture operating under Sullivan & Company Holdings LLC. Its public-facing website describes the company as "engineering a new class of cancer-killing antibodies," indicating a therapeutic focus on antibody-based cancer treatments. Public information is extremely limited, and no disclosed lead candidates, targets, clinical-stage assets, or partnered programs were identified from readily available sources. Based on the available evidence, the company seems to be active but still in a very early, likely preclinical stage. The exact corporate positioning is somewhat ambiguous because business-directory sources also classify the legal entity as an investment or holding platform rather than a fully described operating biopharma company.